Published online 19 February 2009
Haematologica, Vol 94, Issue 4, 496-506 doi:10.3324/haematol.13612
Copyright © 2009 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chamuleau, M. E.D.
Right arrow Articles by van de Loosdrecht, A. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chamuleau, M. E.D.
Right arrow Articles by van de Loosdrecht, A. A.
Related Collections
Right arrowRelated Article

Myelodysplastic Syndromes

Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome

Martine E.D. Chamuleau1, Theresia M. Westers1, Linda van Dreunen1, Judith Groenland1, Adri Zevenbergen1, Corien M. Eeltink1, Gert J. Ossenkoppele1, Arjan A. van de Loosdrecht1

1 Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands

Correspondence: Martine E.D. Chamuleau, MD, Department of Hematology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands. E-mail:m.chamuleau{at}vumc.nl

Background: An activated immune system has been observed in patients with myelodysplastic syndrome but its exact contribution to disease development and control is not fully clarified. On the one hand an activated and skewed T-cell repertoire has been reported, but on the other hand, decreased natural killer cell function has been found. Immune activation could reflect undesired autoimmune reactions against normal hematopoietic precursor cells as well as effective immune-surveillance against dysplastic clones.

Design and Methods: We have investigated immune effector cells (lymphocyte subsets, lymphocyte activation markers, and natural killer cells) of 40 low and intermediate risk myelodysplastic syndrome patients and compared them to those of 10 age-matched healthy donors. Furthermore, we have analyzed the cytotoxic capacity of effector cells against autologous bone marrow hematopoietic precursor cells of 8 myelodysplastic syndrome patients and 2 healthy donors.

Results: In myelodysplastic syndrome patients, we have found an activated state of lymphocytes, determined by increased percentages of effector T cells with cytotoxic profile, more skewing of the T-cell receptor Vβ (TCR-Vβ) repertoire, and decreased frequencies of regulatory T cells, when compared to healthy donors. The percentage of natural killer cells did not differ between myelodysplastic syndrome patients and healthy donors, but natural killer cells of myelodysplastic syndrome patients expressed increased levels of granzyme B. Finally, we have demonstrated non-MHC restricted autologous cytotoxicity up to 90% against aberrant hematopoietic precursor cells, presumably mediated by natural killer cells.

Conclusions: Our data point to a role for active immune-surveillance in myelodysplastic syndrome, as demonstrated by activated T cells and TCR-Vß skewing. Autologous cytotoxicity against hematopoietic precursor cells was natural killer cell dependent, which points to an additional role for the innate immune system in immune-surveillance of myelodysplastic syndrome patients.

Key words: myelodysplastic syndrome, lymphocytes, immune-surveillance, immunetherapy, autologous cytotoxicity.


Related Article

Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance
A. John Barrett, Elaine Sloand
Haematologica 2009 94: 449-451. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 NEJMHome page
A. Tefferi and J. W. Vardiman
Myelodysplastic Syndromes
N. Engl. J. Med., November 5, 2009; 361(19): 1872 - 1885.
[Full Text] [PDF]

Home page
 haematolHome page
A. J. Barrett and E. Sloand
Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance
Haematologica, April 1, 2009; 94(4): 449 - 451.
[Full Text] [PDF]